Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.
Journal: Oncology and therapy
Published: July 13, 2020
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2016
Treatment Patterns and Costs Of Neoadjuvant Systemic Therapies (NAT) For Early Breast Cancer (EBC): A Retrospective Claims Analysis.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 01, 2014
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: September 18, 2013
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Journal: Cancer biology & therapy
Published: June 25, 2013
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Journal: Clinical colorectal cancer
Published: April 17, 2013
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Journal: Cancer investigation
Published: October 16, 2012
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.
Journal: Clinical breast cancer
Published: September 30, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026